David Schrama

8.5k total citations · 1 hit paper
140 papers, 5.6k citations indexed

About

David Schrama is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, David Schrama has authored 140 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 109 papers in Oncology, 43 papers in Molecular Biology and 43 papers in Immunology. Recurrent topics in David Schrama's work include Polyomavirus and related diseases (59 papers), Full-Duplex Wireless Communications (40 papers) and Antenna Design and Analysis (35 papers). David Schrama is often cited by papers focused on Polyomavirus and related diseases (59 papers), Full-Duplex Wireless Communications (40 papers) and Antenna Design and Analysis (35 papers). David Schrama collaborates with scholars based in Germany, Austria and United States. David Schrama's co-authors include Jürgen C. Becker, Roland Houben, Ralph A. Reisfeld, Per thor Straten, Mads Hald Andersen, Selma Ugurel, Cathrin Ritter, Sonja Hesbacher, Paul Nghiem and Juergen C. Becker and has published in prestigious journals such as Cell, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

David Schrama

135 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antibody targeted drugs as cancer therapeutics

2006 597 citations David Schrama, Jürgen C. Becker et al. profile →

Peers

Countries citing papers authored by David Schrama

Since Specialization

Citations

This map shows the geographic impact of David Schrama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Schrama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Schrama more than expected).

Fields of papers citing papers by David Schrama

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Schrama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Schrama. The network helps show where David Schrama may publish in the future.

Co-authorship network of co-authors of David Schrama

This figure shows the co-authorship network connecting the top 25 collaborators of David Schrama. A scholar is included among the top collaborators of David Schrama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Schrama. David Schrama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Update Merkel-Zell-Karzinom 2024 ·PUBLISSO (German National Library of Medicine) ·Jürgen C. Becker, Andreas Stang, David Schrama, Ralf Gutzmer, Selma Ugurel	1
2	Loss of p14 diminishes immunogenicity in melanoma via non‐canonical Wnt signaling by reducing the peptide surface density 2024 ·Molecular Oncology ·(unknown), Corinna Kosnopfel, D. S. Faber, (unknown), (unknown), (unknown), Andreas Schlösser, (unknown), David Liu, David Schrama, Roland Houben, Dirk Schadendorf, Matthias Goebeler, Svenja Meierjohann, Bastian Schilling	1
3	Gene fusions in poroma, porocarcinoma and related adnexal skin tumours: An update 2023 ·Histopathology ·Thibault Kervarrec, Daniel Pissaloux, Franck Tirode, Arnaud de la Fouchardière, Pierre Sohier, É. Frouin, Aymeric Hamard, Roland Houben, David Schrama, Anne Barlier, B. Cribier, Maxime Battistella, Nicolas Macagno	13
4	Cutaneous epithelioid haemangiomas show somatic mutations in the mitogen‐activated protein kinase pathway 2021 ·British Journal of Dermatology ·Katja Maurus, Corinna Kosnopfel, Hermann Kneitz, Silke Appenzeller, David Schrama, Valerie Glutsch, Sabine Roth, (unknown), Mathias T. Rosenfeldt, Lino Möhrmann, Martina Fröhlich, Daniel Hübschmann, Albrecht Stenzinger, Hanno Glimm, Stefan Fröhling, Matthias Goebeler, Andreas Rosenwald, Heinz Kutzner, Bastian Schilling	2
5	Identification of potential inhibitors targeting BRAF-V600E mutant melanoma cells 2020 ·Journal of the American Academy of Dermatology ·Onat Kadioglu, Mohamed E.M. Saeed, Henry Johannes Greten, (unknown), David Schrama, Wynand P. Roos, Thomas Efferth	2
6	Merkel Cell Polyomavirus Large T Antigen is Dispensable in G2 and M-Phase to Promote Proliferation of Merkel Cell Carcinoma Cells 2020 ·Viruses ·Roland Houben, (unknown), Sonja Hesbacher, Thibault Kervarrec, David Schrama	1
7	Merkel cell carcinoma-derived exosome-shuttle miR-375 induces fibroblast polarization by inhibition of RBPJ and p53 2020 ·Oncogene ·Kaiji Fan, Ivelina Spassova, (unknown), Cathrin Ritter, (unknown), Anja Lange, Thilo Gambichler, Niels Ødum, David Schrama, Dirk Schadendorf, Selma Ugurel, Jürgen C. Becker	40
8	Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma 2020 ·Clinical Cancer Research ·Ivelina Spassova, Selma Ugurel, Patrick Terheyden, Antje Sucker, Jessica C. Hassel, Cathrin Ritter, Linda Kubat, (unknown), (unknown), (unknown), Lukas Peiffer, Rajiv Kumar, David Schrama, Daniel Hoffmann, Dirk Schadendorf, Jürgen C. Becker	52
9	Highly Expressed miR-375 is not an Intracellular Oncogene in Merkel Cell Polyomavirus-Associated Merkel Cell Carcinoma 2020 ·Cancers ·Kaiji Fan, Armin Zebisch, (unknown), David Schrama, Jürgen C. Becker	15
10	Characterization of six Merkel cell polyomavirus‐positive Merkel cell carcinoma cell lines: Integration pattern suggest that large T antigen truncating events occur before or during integration 2019 ·International Journal of Cancer ·David Schrama, (unknown), Christian Adam, Cathrin Ritter, Ulrike Kaemmerer, Eva Klopocki, Eva‐Maria König, Jochen Utikal, Jürgen C. Becker, Roland Houben	42
11	MCPyV Large T Antigen-Induced Atonal Homolog 1 Is a Lineage-Dependency Oncogene in Merkel Cell Carcinoma 2019 ·Journal of Investigative Dermatology ·Kaiji Fan, (unknown), Cathrin Ritter, (unknown), Thilo Gambichler, Ugo Moens, Masahiro Shuda, David Schrama, Jürgen C. Becker	31
12	Polyomavirus-Positive Merkel Cell Carcinoma Derived from a Trichoblastoma Suggests an Epithelial Origin of this Merkel Cell Carcinoma 2019 ·Journal of Investigative Dermatology ·Thibault Kervarrec, (unknown), Silke Appenzeller, M. Samimi, E. Maubec, B. Cribier, Lydia Deschamps, (unknown), (unknown), Patricia Berthon, Annie Lévy, Guilhem Bousquet, Anne Tallet, Antoine Touzé, Serge Guyétant, David Schrama, Roland Houben	28
13	Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma 2018 ·Clinical Cancer Research ·Kaiji Fan, Cathrin Ritter, Paul Nghiem, Astrid Blom, Monique Verhaegen, Andrzej A. Dlugosz, Niels Ødum, Anders Woetmann, Richard W. Tothill, Rodney J. Hicks, Michael Sand, David Schrama, Dirk Schadendorf, Selma Ugurel, Jürgen C. Becker	43
14	Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC 2017 ·Cancer Immunology Immunotherapy ·Jürgen C. Becker, Andreas Stang, Axel zur Hausen, Nicole Fischer, James A. DeCaprio, Richard W. Tothill, Rikke Lyngaa, (unknown), Cathrin Ritter, Paul Nghiem, Christopher K. Bichakjian, Selma Ugurel, David Schrama	73
15	Non-reproducible sequence artifacts in FFPE tissue: an experience report 2017 ·Journal of Cancer Research and Clinical Oncology ·(unknown), Cathrin Ritter, Selma Ugurel, Lorenzo Cerroni, Mathias Stiller, Thomas Bogenrieder, Flavio Solca, David Schrama, Jürgen C. Becker	9
16	Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma 2017 ·Scientific Reports ·Cathrin Ritter, Kaiji Fan, Annette Paschen, (unknown), Soldano Ferrone, Paul Nghiem, Selma Ugurel, David Schrama, Jürgen C. Becker	107
17	T-cell Responses to Oncogenic Merkel Cell Polyomavirus Proteins Distinguish Patients with Merkel Cell Carcinoma from Healthy Donors 2014 ·Clinical Cancer Research ·Rikke Lyngaa, Natasja Wulff Pedersen, David Schrama, Charlotte Albæk Thrue, Dafina Ibrani, Özcan Met, Per thor Straten, Paul Nghiem, Jürgen C. Becker, Sine Reker Hadrup	76
18	Transcriptome-Wide Studies of Merkel Cell Carcinoma and Validation of Intratumoral CD8+ Lymphocyte Invasion As an Independent Predictor of Survival 2011 ·Journal of Clinical Oncology ·Kelly G. Paulson, Jayasri G. Iyer, Andrew Tegeder, Renee Thibodeau, Janell M. Schelter, S Koba, David Schrama, William Simonson, Bianca D. Lemos, David R. Byrd, David M. Koelle, Denise A. Galloway, J. Helen Leonard, Margaret M. Madeleine, Zsolt B. Argényi, Mary L. Disis, Juergen C. Becker, Michele A. Cleary, Paul Nghiem	224
19	Antibodies to Merkel Cell Polyomavirus T Antigen Oncoproteins Reflect Tumor Burden in Merkel Cell Carcinoma Patients 2010 ·Cancer Research ·Kelly G. Paulson, Joseph J. Carter, Lisa Johnson, (unknown), Jayasri G. Iyer, David Schrama, Juergen C. Becker, Margaret M. Madeleine, Paul Nghiem, Denise A. Galloway	157
20	Merkel Cell Polyomavirus-Infected Merkel Cell Carcinoma Cells Require Expression of Viral T Antigens 2010 ·Journal of Virology ·Roland Houben, Masahiro Shuda, (unknown), David Schrama, Huichen Feng, Yuan Chang, Patrick S. Moore, Jürgen C. Becker	339

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact